Their main innovation relates to Ensoma Engine, an ingenious vector engineered specifically to deliver genetic material directly to hematopoietic stem-cells or other cells arising from them. This would erase the need to collect stem cells from the patient or use chemotherapy for myeloablative conditioning and potentially yield the single injection therapy. If successful, this would dramatically simplify the storage, logistics and increase the availability of this therapy worldwide.